Taxane, Anthracycline Combo Most Effective in Reducing Breast Cancer Recurrence
Combining anthracycline and taxane for early-stage operable breast cancer was more effective than either anthracycline or taxane chemotherapy alone in reducing breast cancer recurrence and death, according to a meta-analysis. Moreover, regimens with higher cumulative doses of anthracycline plus taxane were associated with the greatest benefit, according to a report from Jeremy Braybrooke, BM, PhD, […]
Different Taxanes, Similar Outcomes in Advanced HER2-Positive Breast Cancer
Final results from a routine-practice comparison of taxane agents showed that the drugs offered comparable safety and efficacy in advanced HER2-positive breast cancer. Median progression-free survival (PFS) was about 21 months and median overall survival (OS) was 65 months with dual anti-HER2 therapy and was similar among patients who received paclitaxel or docetaxel, as well […]